Bookmark
Forward
QuickView for xylometazoline (compound)
PubChem
| Name: | xylometazoline |
|---|---|
| PubChem Compound ID: | 14634 |
| Molecular formula: | C16H25ClN2 |
| Molecular weight: | 280.836 g/mol |
| Synonyms: |
2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline hydrochloride; 8057-34-9; Xylometazoline hydrochloride; 1218-35-5; Otrivin; EINECS 214-936-4; 526-36-3; Neo-Synephrine II; Otrivine; 28096-10-8.
show more » |
DrugBank
Identification
| Name: | xylometazoline |
|---|---|
| Name (isomeric): | DB06694 |
| Drug Type: | small molecule |
| Synonyms: |
Xylomethazoline
|
| Brand: | Otriven, Otrix, Otrivine, Otrivin |
| Category: | Adrenergic alpha-Agonists, Sympathomimetics, Nasal Decongestants |
| CAS number: | 526-36-3 |
Pharmacology
| Indication: | It is used for treating nasal congestion and minor inflammation due to allergies or colds. |
|---|---|
| Pharmacology: | Xylometazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion. The sympathomimetic action of xylometazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (8-12 hours) decongesting effect. |
| Mechanism of Action: | Xylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion. |
Targets
